International Multicenter Randomized Double Blind Phase III Clinical Trial Comparing Safety and Efficacy of BCD-022 (CJSC BIOCAD, Russia) Used With Paclitaxel to Herceptin (F. Hoffmann-La Roche Ltd, Switzerland) Used With Paclitaxel in the First-line Treatment of HER2-positive Metastatic Breast Cancer Patients
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Trastuzumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Biocad
- 24 Oct 2016 Status changed from active, no longer recruiting to completed.
- 11 Oct 2016 Primary endpoint (Overall Response Rate) has been met, according to results presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Results analysing safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History